Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways

Collaborations, Agility Also Key

Jun 28 2021

• By Anju Ghangurde

Amgen — Amgen chief signals opportunities to accelerate drug development • Source: Alamy

Related Content

Woodcock Attributes Aduhelm Approval Controversy To ‘Process Problems’

Jun 23 2021

Does The Pandemic Present Opportunities To Rethink Regulatory Approaches?

Sep 15 2020

Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth

Feb 03 2021

Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Jun 08 2021

Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

May 29 2021

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Mar 04 2021

Start Designing Vaccines For The Next Pandemic, Urges NIH Chief

Jun 23 2021

Related Companies

Amgen, Inc.

Biocon, Ltd.

Biogen, Inc.

Eisai Co., Ltd.

Five Prime Therapeutics, Inc.

Eli Lilly and Company

Additional Topics

Asia Pacific Coronavirus COVID-19 Research & Development BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window